The intention is to support earlier and more efficient engagement between innovators and CDMO teams
Cell and gene therapy CDMO eXmoor Pharma has collaborated with University College London (UCL) to accelerate the development of novel cell and gene therapies from academic research into clinical application.
“The strength of the UK’s academic science has always been clear but getting groundbreaking therapies from the lab to patients requires a collaborative approach,” said eXmoor founder and CEO Angela Osborne.
“This partnership with UCL TRO reflects our shared belief that supporting translational research with practical, GMP-ready solutions is the key to unlocking meaningful outcomes for patients. We’re pleased to play a role in helping academic innovation become clinical reality.”
The intention is to support earlier and more efficient engagement between UCL innovators and eXmoor’s multidisciplinary teams to reduce the risk, cost and complexity of technical development.
“Through this strategic partnership, we look forward to connecting UCL researchers with eXmoor’s expertise, supporting closer collaboration with industry and the development of practical, scalable plans that could help realise therapeutic potential,” said UCL’s head of the TRO Pamela Tranter.
UCL innovators and UCL’s Translational Research Office (TRO) will receive earlier access to CMC expertise, development capabilities and clinical manufacturing support. Academic teams will also receive early access to:
-
CMC consulting and regulatory strategy support
-
Laboratory capacity and expertise in process and analytical development
-
GMP manufacturing for early clinical studies
-
Cross-modality insight across viral vectors, autologous and allogeneic cell therapies, and RNA technologies
Structured, early engagement is expected to mould more practical and commercially aware development strategies that include opportunities for grant input, regular consultancy clinics and joint events.
